WO2002031131A1 - Nouvelle phospholipase a1 (pla1) - Google Patents
Nouvelle phospholipase a1 (pla1) Download PDFInfo
- Publication number
- WO2002031131A1 WO2002031131A1 PCT/JP2001/007106 JP0107106W WO0231131A1 WO 2002031131 A1 WO2002031131 A1 WO 2002031131A1 JP 0107106 W JP0107106 W JP 0107106W WO 0231131 A1 WO0231131 A1 WO 0231131A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- polynucleotide
- compound
- activity
- transformant
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 181
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 133
- 229920001184 polypeptide Polymers 0.000 claims abstract description 124
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 63
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 63
- 239000002157 polynucleotide Substances 0.000 claims abstract description 63
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 47
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims abstract description 38
- 230000000694 effects Effects 0.000 claims description 63
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 33
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 230000003993 interaction Effects 0.000 claims description 19
- 230000000295 complement effect Effects 0.000 claims description 17
- 150000007523 nucleic acids Chemical group 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 13
- 230000009471 action Effects 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 6
- 102000015439 Phospholipases Human genes 0.000 claims description 6
- 108010064785 Phospholipases Proteins 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 238000007792 addition Methods 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 230000001766 physiological effect Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 230000004075 alteration Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 9
- 108010013563 Lipoprotein Lipase Proteins 0.000 abstract description 8
- 239000005557 antagonist Substances 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 abstract 7
- 210000004027 cell Anatomy 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 33
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 24
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 24
- 102000004882 Lipase Human genes 0.000 description 23
- 108090001060 Lipase Proteins 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 21
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 239000004367 Lipase Substances 0.000 description 18
- 235000019421 lipase Nutrition 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 239000000523 sample Substances 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229920000747 poly(lactic acid) Polymers 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 9
- 102000011420 Phospholipase D Human genes 0.000 description 9
- 108090000553 Phospholipase D Proteins 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 210000001550 testis Anatomy 0.000 description 8
- 108091035707 Consensus sequence Proteins 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000009739 binding Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- -1 phosphatidic acid Chemical class 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101100083853 Homo sapiens POU2F3 gene Proteins 0.000 description 2
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101100058850 Oryza sativa subsp. japonica CYP78A11 gene Proteins 0.000 description 2
- 101150059175 PLA1 gene Proteins 0.000 description 2
- 102100026466 POU domain, class 2, transcription factor 3 Human genes 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 108010090932 Vitellogenins Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 102000005311 colipase Human genes 0.000 description 2
- 108020002632 colipase Proteins 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101710110315 Bacchus Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 description 1
- 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 description 1
- 101001134456 Homo sapiens Pancreatic triacylglycerol lipase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 102000043296 Lipoprotein lipases Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 1
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 description 1
- 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 description 1
- 241000555303 Mamestra brassicae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000032976 Neuroendocrine carcinoma of pancreas Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 102000046759 human PNLIP Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 125000005539 phosphatidic acid group Chemical group 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 101150013341 pla gene Proteins 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel lipase, in particular, a phospholipase (phospho1ipaseA, hereinafter sometimes also referred to as PLA). More specifically, a peptide or polypeptide having all or part of the amino acid sequence of the novel PLA, a polynucleotide encoding the peptide or polypeptide, a recombinant vector containing the polynucleotide, A transformant transformed with a vector, a method for producing a peptide or polypeptide using the transformant, an antibody against the peptide or polypeptide, a method for identifying a compound using the same, Compound, activity-inhibiting compound or activity-activating compound acting on the polypeptide or the polynucleotide, a pharmaceutical composition related thereto, a method for producing the same, a therapeutic method using the pharmaceutical composition, and a disease related thereto Related to the diagnostic method.
- PL is an enzyme that hydrolyzes the ester bond at position 1 of glycerol in glycerophospholipids. To date, the presence of this enzyme activity has been detected in various organs, and several PLAs, which are distinguished by substrate specificity, have been reported.
- c DNA-cloned products include bee venom PLA (Dolm 1) and PS-PLA (phosphatidylserine (PS) and lysophosphatidylserine (1ysoPS)).
- LPA lysophosphatidic acid
- B.B.A. lysophosphatidic acid
- the major effects of LPA include a blood pressure increasing effect (Lipids, 13, 572-574, 1978) and a platelet aggregation effect (Am. J. Pathol., 96, 4).
- the P is an intracellular enzyme and is considered as a factor that determines the turnover of the fatty acid at the sn-1 position of phosphatidic acid, which is the center of phospholipid metabolism (J. Bol. Chem. ., 273, 5468-54 77, 1998).
- human testis PA-PLA also hydrolyzes -phosphatidylethanolamine (PE) and phosphatidylinositol (PI) depending on the reaction conditions.
- PE phosphatidylethanolamine
- PI phosphatidylinositol
- the present invention is to find a novel substance related to P, which is a biocatalyst of LPA, which can be a cause of a rather adverse effect in various aspects as described above, and to enable control of LPA in vivo. Is one of the purposes. Disclosure of the invention
- the present invention provides: (1) a polypeptide selected from the group consisting of:
- ⁇ ⁇ a polypeptide having a mutation such as deletion, substitution, addition or insertion of one or several amino acids in the amino acid sequence and having an activity of decomposing phosphatidic acid;
- SEQ ID NO: 1 or 2 in the sequence listing A polypeptide having at least about 8 consecutive amino acid sequences of the amino acid sequence described in (3), a polynucleotide encoding the above 1 or 2 polypeptide or peptide, or a complementary strand thereof, (4) A polynucleotide that hybridizes under selective conditions with the above-mentioned 3 polynucleotide or its complementary strand, (5) at least about 1 nucleotide of the nucleotide sequence of SEQ ID NO: 3 or 4 or its complementary sequence A polynucleotide represented by five consecutive nucleotide sequences; (6) a recombinant vector comprising any one of the polynucleotides of (3) to (5) above.
- a transformant transformed with the recombinant vector of (6) (8) a method of culturing the transformant of (7), wherein the polypeptide or polypeptide of (1) or (2) is (9) an antibody that immunologically recognizes the polypeptide or peptide of (1) or (2), (10) the antibody of (9), which suppresses the activity of decomposing phosphatidic acid, (11)
- a method for identifying a compound that interacts with the above-mentioned 1 polypeptide to inhibit or activate its activity and / or a compound that interacts with the above 3 or 4 polynucleotide to inhibit or promote its expression is
- the interaction of the compound with the compound to be cleaned is evaluated by evaluating the interaction of the compound (such interaction may provide a detectable signal in response to the interaction of the polypeptide or polynucleotide with the compound).
- the compound is then detected by detecting the presence or absence or a change in the signal resulting from the interaction of the compound with the polypeptide or polynucleotide, thereby allowing the compound to bind to the polypeptide or polynucleotide.
- a second component capable of providing a detectable signal in response to the interaction
- a method comprising: (15) a compound that interacts with the polypeptide (1) to inhibit or activate its activity, or interacts with the polynucleotide (3) or (4) to express its expression.
- FIG. 1 is a diagram illustrating an array of a new PLA (short-t ype) and characteristics of the array.
- a double underline indicates a signal sequence
- an underline indicates a glycosylation site
- a double arrow underline indicates a lipase consensus sequence and a lid region
- boxes S, D, and H indicate active triads.
- FIG. 4 is a diagram illustrating an array of (short—type) and characteristics of the array.
- a double underline indicates a signal sequence
- an underline indicates a predicted glycosylation site
- an underlined double arrow indicates a lipase consensus sequence and a lip region
- S, D, and H enclosed in boxes indicate active triads.
- FIG. 3 is a diagram for explaining a bioassay system using a novel PLA-expressing cell and an LPA receptor EDG7-expressing cell into which Fura2 has been incorporated, in order to examine the action of the novel PLA.
- FIG. 2 is a view showing the involvement of PLD in LPA production mediated by PLD.
- FIG. 4 (B) is a diagram showing a concentration-action curve of 1-ol eyl-LPA in EDG7-expressing cells.
- the novel PLA which is provided in the present invention, is obtained by obtaining the cDNA as a substance having a novel amino acid sequence from a cDNA library.
- the presence of the novel PLA of the present invention in human testis was confirmed by Northern plotting.
- the novel PLA of the present invention has the following properties. Acts on phospholipids, especially phosphatidic acid (PA), to produce LPA. It has consensus sequences and catalytic triads conserved in the lipase family and amino acids that are considered lids. Also, the homology with known PLs is less than about 40%.
- the amino acid sequence of the novel PLA of the present invention is the polypeptide described in SEQ ID NO: 1 or 2 in the sequence listing. Further, the polypeptide or the peptide of the present invention is selected from a polypeptide or a peptide containing at least a part of the polypeptide described in SEQ ID NO: 1 or 2 in the sequence listing.
- the selected polypeptide or peptide is the same as the polypeptide set forth in SEQ ID NO: 1 or 2 in the sequence listing, but not less than about 40%, preferably not less than about 70%, and more preferably about 80% on the amino acid sequence. Above, more preferably It has about 90%, particularly preferably about 95% or more homology.
- Polypeptides or peptides having this homology can be selected based on the activity of degrading phospholipids, particularly phosphatidic acid, and / or the presence of substrate specificity for phosphatidic acid.
- the above-mentioned degradation activity can be measured by a known method, for example, a method using a radioisotope (RI) -labeled substrate, a fluorescent substrate, or a chromogenic substrate, or a method described in Examples (J. Biochem, 103, 442). — 447, 1988) (J. Biochem., 117, 1280-1287, 1995) (J. Bioch em., 101, 53—61, 1987) (J. Chem., 235, 2595-2599, 1960) (J.
- RI radioisotope
- the polypeptide or peptide of the present invention includes a polypeptide or a peptide having a partial sequence of the polypeptide set forth in SEQ ID NO: 1 or 2 in the Sequence Listing, such as a reagent, a standard, or an immunogen.
- an immunologically identifiable polypeptide or peptide is the subject of the present invention.
- These peptides may be used alone or as carriers (eg, keyhole limpet hepatin or egg white) as reagents or standards, or antigens to generate antibodies specific for the novel PL, as described below. Lupmin, etc.), and those bound with other proteins or substances as described above are also included in the scope of the present invention.
- the activity of degrading phospholipids, particularly phosphatidic acid, and / or the presence of substrate specificity for phosphatidic acid can be used as an indicator.
- polypeptide or a peptide comprising an amino acid sequence having a mutation such as addition, insertion or insertion.
- Means for deletion, substitution, addition or insertion are known per se. For example, site-directed mutagenesis, homologous recombination, primer extension or polymerase chain amplification (PCR) may be used alone or in combination as appropriate.
- PCR polymerase chain amplification
- polypeptide or peptide of the present invention is included in the scope of the present invention regardless of the presence or absence of a sugar chain, at least one glycosylation site is retained because the sugar chain may affect the activity. It is preferable that it is done.
- a PLA similar to the polypeptide represented by the amino acid sequence of SEQ ID NO: 1 or 2 in the Sequence Listing a polypeptide having an activity or a minimum activity unit (region or domain) thereof is also provided.
- polypeptides having altered activity intensity or substrate specificity are provided. These are useful, for example, as PLA activity-like substances or PLA antagonists, or in screening for PLA, a substance that regulates activity, and the like.
- homologous gene products of animal species other than human are naturally included in the scope of the present invention.
- another protein such as allipolytic phosphatase is added to the N-terminal side or C-terminal side.
- immunoglobulin Fc fragment such as 3-galactosidase, IgG, etc. or peptide such as FLAG-tag is added directly or indirectly via a linker peptide using genetic engineering techniques. This is easy for those skilled in the art, and polypeptides and the like to which these other substances are bound are also included in the scope of the present invention. (Polynucleotide)
- the polynucleotide of the present invention and the complementary strand thereof may be a polynucleotide or an amino acid sequence of the polypeptide of the present invention, for example, a polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 or 2 in the Sequence Listing. It means the complementary strand to the polynucleotide.
- SEQ ID NO: 3 or 4 in the sequence listing showing preferred polynucleotides, base numbers from A (adenine) of base number 1 15 to A (adenine) of base number 1 494 or A (adenne) of base number 11 are shown, respectively. It is estimated that up to 1 453 A (adenine) is a coding region.
- atg to gtg which codes from M (Met) at amino acid number 1 to V (V a1) at amino acid number 13 in the amino acid sequence of SEQ ID NO: 1, encodes a signal sequence It is presumed that.
- the present invention provides a polynucleotide encoding the amino acid sequence of a polypeptide or a peptide of the present invention, for example, the amino acid sequence of SEQ ID NO: 1 or 2 in the sequence listing, preferably SEQ ID NO: 3 or 4 in the sequence listing.
- the present invention provides a polynucleotide that hybridizes under selective conditions, preferably under stringent conditions, to a polynucleotide represented by the following nucleotide sequence or a region corresponding to the complementary strand thereof. The method of hybridization is described in, for example, Sambrook et al.
- the selective hybridization condition is a desired condition.
- a nucleic acid having a desired homology with a specific probe for example, a nucleic acid encoding the PLA of the present invention of SEQ ID NO: 3
- Nucleic acids eg, conditions that do not hybridize to nucleic acids of lower homology.
- the melting temperature (Tm) is used as an indicator of the stability of a double-stranded molecule (hybrid) of a nucleic acid, which is based on the strand length, base composition and chemical conditions (ionic strength, chemical denaturing agent). Hybridization is usually carried out at temperatures below Tm.
- the empirical experimental formula has been obtained for the Tm value of a completely complementary hybrid with a DNA, RNA or oligonucleotide probe (Human Molecular Genetics, Tom Strachan and Andrew P. Read). Supervised by Masanori Muramatsu, Medical. Sci-Fis-National, 1997, etc.).
- the hybridization temperature should be 5 ° C lower or higher than Tm (preferably lower than Tm) and the stability of the hybrid should be maintained. For this, it is necessary to lower the hybridization temperature about 5 ° C below Tm for each pair of unpaired bases.
- T m (° C) 81.5 ° C + 1 6.61 og M + 0.41 (% G +% C)-500 / n-0.61 (% Formamide)
- M is the monovalent cation strength of the solution (mo 1 / s)
- n is the length of the duplex in base pairs] and contains 1% unpaired base
- the standard of the hybridization temperature is determined from the Tm of the perfect complementation hybrid by, for example, 55 ° C, preferably 40 ° C, more preferably 25 ° C, further preferably 10 ° C, particularly preferably 5 ° C.
- ° C lower temperature allows selective selection of desired homologous nucleic acids Can be hybridized to Specifically, there is a method in which the method such as Shaw is partially modified. That is, a filter (eg, a nylon membrane or a nitrocellulose filter) to which nucleic acid is bound is filtered at 65 ° C at 3 ° SSC containing 0.1% SDS (Standard Saline Citrate: 1 x SSC is 0.1%). 5M NaC1, 0.01M 5M sodium citrate), then wash with 50% formamide, 5X Denhardt's solution, 0.1% SDS, 250gZm 1 5XSSCP (I x SSCP is, 0. 1 5M N a C 1 , 0.
- a filter eg, a nylon membrane or a nitrocellulose filter
- the nucleotide sequence of SEQ ID NO: 3 or 4 in the sequence listing or its complement is at least about 40%, for example, about 70% or more, preferably about 80% or more, more preferably about 90% or more, and still more preferably about 95% or more.
- the polynucleotide of the present invention is a polynucleotide comprising a sequence of 10 or more nucleotides, preferably 15 or more, more preferably ⁇ 20, which corresponds to the designated base sequence region. Ligated nucleotides and their complementary strands.
- polynucleotides may be used in the production of the polypeptides of the present invention, for example, as a nucleic acid encoding a novel PLA, for example, as a probe or primer for detecting the gene or mRA, or for regulating gene expression. It is useful as an antisense oligonucleotide or the like. In that sense, the polynucleotides and oligonucleotides of the present invention include those corresponding to the untranslated region as well as the translated region. For example, in order to specifically inhibit the expression of novel P by antisense, it is assumed that the nucleotide sequence of a region unique to the new PLA 1 other than the consensus sequence region conserved in the lipase family is used. .
- the use of conserved sequences could simultaneously suppress the expression of multiple lipases, including novel PLA.
- determination of the nucleotide sequence encoding a novel PLA or a polypeptide having similar activity is performed.
- the expressed protein is confirmed using a known protein expression system, and its physiological activity, particularly phosphatidic acid, is determined.
- example embodiment may utilize germ technology ribosome system derived from rabbit reticulocyte, etc. (N ature, 1 7 9, 1 6 0 ⁇ 1 6 1 N 1 9 5 7) .
- the present invention comprises the present invention by a gene recombination technique using a host known per se such as Escherichia coli, yeast, Bacillus subtilis, insect cells, animal cells and the like. New PLA and its derived peptides and polypeptides are available.
- insect cells were used, but it is needless to say that the present invention is not limited thereto (Japanese Patent Nos. 2,129,487 and 2,644,444: Recombination Baculourovirus expression vector production method and polypeptide synthesis).
- PLA encoded by the novel PLA gene of the present invention
- a host such as a polypeptide or an animal cell which is a host capable of adding a sugar chain to the peptide. Transformation is performed by a known method. For example, a host is transformed using a plasmid, a chromosome, a virus, or the like as a lebricon.
- a more preferable system is an integration method into a chromosome in consideration of the stability of the gene.
- the vector is selected according to the type of the selected host, and includes a gene sequence to be expressed and a gene sequence carrying information on replication and control as components.
- the combination is classified into prokaryotic cells and eukaryotic cells, and the promoter, ribosome binding site, evening motif, signal sequence, enhancer, etc. can be used in combination by a method known per se.
- the baculovirus system was used, but it is needless to say that the present invention is not limited to this.
- the transformant is cultured under conditions suitable for the culture conditions of each host known per se. The cultivation is based on the enzymatic activity of peptides and polypeptides composed of novel P and its derivatives, which are expressed and produced, especially phosphatidic acid. May be performed using the enzyme activity of degrading the enzyme as an index, or may be produced by subculture or batch using the amount of the transformant in the medium as an index.
- the antibody is a novel PLA! And the antigenic determinants of peptides or polypeptides derived from the same and their derivatives.
- the antigen may be a novel PLA or a fragment thereof, and is composed of at least 8, preferably at least ⁇ 10, more preferably at least 12, more preferably 15 or more amino acids.
- a new PLA! It is preferable to use a region consisting of a sequence unique to This amino acid sequence does not necessarily need to be homologous to SEQ ID NO: 1 or 2 in the sequence listing, and is preferably an exposed site on the three-dimensional structure of the protein. It is also effective that the site has a continuous amino acid sequence.
- Antibodies are not particularly limited as long as they bind or recognize a peptide or polypeptide immunologically comprising a novel PLA and its derivative. And The presence or absence of this binding or recognition is determined by a known antigen-antibody binding reaction.
- a peptide or polypeptide comprising the novel PL of the present invention and a derivative thereof is used alone or in the presence of an adjuvant in the presence or absence of an adjuvant to bind a body fluid to an animal. It is performed by inducing immunity such as sexual response and ⁇ or cellular response.
- the carrier is not particularly limited as long as it does not cause harmful effects on the host, and examples thereof include cellulose, polymerized amino acids, and albumin.
- the polyclonal antibody is obtained by a known antibody recovery method from serum.
- a preferred means is immunoaffinity chromatography.
- antibody-producing cells for example, spleen or lymph node-derived
- a perpetual proliferating cell for example, ⁇ 3 ⁇ 63
- a hybridoma is produced by fusion with a myeloma cell line (eg, 8 strains of Ag).
- the PLA! A hybridoma producing an antibody that specifically recognizes the hybridoma is selected, and the antibody is recovered from a culture solution of the hybridoma.
- a polyclonal antibody or a monoclonal antibody capable of inhibiting P and A activity can directly bind to the novel PL of the present invention and control its activity, and can be used for the production of phospholipids, especially PA, from PA. Control can be performed easily. Therefore, treatment and treatment of various adverse diseases associated with LPA And / or useful for prevention.
- the peptide or polypeptide consisting of the novel P and A thus prepared and its derivatives, the polynucleotide encoding the same and its complementary strand, and the amino acid sequence and base sequence thereof are transformed based on the information.
- Cells, or a protein synthesis system using them, and an antibody that immunologically recognizes a peptide or polypeptide consisting of a novel PL and its derivative can be used alone or in combination with a new PL and its antibody.
- the present invention provides an effective means for a method for identifying or screening a substance or a modulator for activity against a peptide and a polypeptide or a polypeptide consisting of a derivative, for example, an activity inhibitor or an activity activator.
- peptides or polypeptides for example, selection of antagonists by drug design based on the three-dimensional structure of peptides or polypeptides, selection of expression regulators at the gene level using a protein synthesis system, selection of antibody recognition substances using antibodies, etc. are known per se. It can be used in drug screening systems in Japan.
- the above-mentioned regulation includes inhibition, antagonism, activation, activity promotion, activity activation and the like.
- a peptide or polypeptide comprising the novel PLA of the present invention and a derivative thereof, or a polynucleotide or a transformant of the present invention may be a compound between a screening candidate compound and such a peptide or polypeptide.
- a system that uses a signal that can detect the presence or absence of this interaction, and determine the presence or absence of this signal (marker) or the amount of signal.
- the system that uses a signal include a system that measures the activity of the polypeptide of the present invention, for example, an activity of decomposing a substrate such as PA, or a system that measures the expression level of a polynucleotide. Specific examples are shown in the examples.
- a transformant expressing the novel PLA of the present invention or a polypeptide comprising a derivative thereof, a novel PLA expressed in the transformant Alternatively, using a compound and the above-mentioned polypeptide or a polypeptide thereof, using another transformant expressing a receptor for lysophosphatidic acid produced by the action of a polypeptide consisting of the derivative on phosphatidic acid.
- the activity or activity of the polypeptide comprising the novel PLA and its derivative or the polynucleotide of the present invention can be determined. It is possible to identify compounds that inhibit or activate physiological effect.
- the transformant include a combination of Sf9 cells expressing the polypeptide of the novel PLA of the present invention or a derivative thereof and Sf9 cells expressing the LPA receptor EDG7. But not limited to this.
- Examples of the signal for detecting the action of the polypeptide comprising the novel PLA of the present invention and a derivative thereof include, for example, intracellular calcium that is increased by binding of LPA to LPA receptor EDG7-expressing cells. What is necessary is just to detect.
- intracellular calcium a measurement method known per se using Fura 2 or the like can be applied.
- the polyp of the present invention The specificity of the compound's action can be confirmed by comparing the reaction in a control system in which the tide or the like is replaced with a homolog of another lipase (ie, a polypeptide or the like) or LPA. Further, each transformant may be replaced with a cell line in which the expression of the corresponding gene has been confirmed.
- Compounds identified in this way are candidate compounds for inhibitors or antagonists of activity or action, antagonists, activators, accelerators or activators for peptides and polypeptides comprising novel P and its derivatives As is available. It can also be used as a candidate compound for expression inhibitors, expression antagonists, expression activators, expression promoters, and expression activators for novel PLA and its derivatives at the gene level. Its effect can be expected to prevent and / or treat various adverse symptoms caused by LPA.
- the candidate compound thus selected can be prepared as a pharmaceutical composition by selecting in consideration of the balance between biological utility and toxicity.
- a novel PL of the present invention and a peptide or polypeptide comprising the derivative thereof, a polynucleotide encoding the same and a complementary chain thereof, a vector comprising these nucleotide sequences, and a novel PLA and a derivative thereof
- An antibody that immunologically recognizes a peptide or polypeptide consisting of a peptide or a polypeptide can be used as a diagnostic marker such as a diagnostic marker or reagent, or can inhibit or antagonize the expression, activity, or action of a novel PLA. It can be used as a pharmaceutical means such as a therapeutic drug utilizing the function of activating, promoting and activating.
- a known formulation means such as a peptide or polypeptide, a protein, a polynucleotide, and an antibody may be introduced according to each subject.
- the pharmaceutical composition can be produced using the novel PLA of the present invention and a peptide or polypeptide, a polynucleotide, a vector, a transformant, an antibody comprising the derivative thereof, and the compound of the present invention. It is.
- the above pharmaceutical composition is useful for treating diseases associated with PLA, particularly novel PLA.
- a diagnostic means it is useful as a means for diagnosing a disease associated with the expression or activity of a peptide or polypeptide comprising the novel PLA of the present invention and a derivative thereof.
- Determining the abundance of the corresponding nucleic acid sequence by utilizing its interaction or reactivity with the nucleic acid sequence, and / or determining the biodistribution of the peptide in an individual; and / or The determination is performed by determining the presence of the peptide, the amount of the peptide present in an individual-derived sample, or the amount of activity. That is, the new P is tested as a diagnostic marker.
- the measurement may be carried out using an antigen-antibody reaction system, an enzyme reaction system, a PCR reaction system, or the like that is known per se. Further, detection of a single nucleotide polymorphism (SNP) by a known method is also a useful diagnostic tool.
- SNP single nucleotide polymorphism
- Rat phospholipase A which specifically hydrolyzes phosphatidylserine, (PS-PLA (J. Biol. Chem., 272, (4), 21)
- a homology search (tb 1 astnsearch) was performed on dbE 3 ⁇ 4 1 (database of Expressed Sequence Tence Tags) using the amino acid sequence of 92-2 198, 1 997) as a probe.
- dbE 3 ⁇ 4 1 database of Expressed Sequence Tence Tags
- an EST sequence having an accession number of AA470035 which had an unknown nucleic acid sequence and a relatively high homology score, was obtained.
- a homology search (b bastnsearch) was performed on GenBank using the nucleic acid sequence of accession number AA470035 as a probe.
- the sequence of accession number AP 006556 and AP 001 347 were clarified. Based on these sequences, a primer was designed, and the sequence was confirmed by PCR using the firststrand prepared from human testis total RNA with the primer Rigo dT as a ⁇ type. Since the sequence on the 5 ′ side was difficult to determine, the primer A (SEQ ID NO: 5) having the nucleotide sequence of AT TT TG TT CAAACAG T GG CT CAG CA and the nucleotide sequence of TT CAAACAG TGG CT CAGCACAG TTT It was confirmed by the 5'-RACE method using primer B (SEQ ID NO: 6) and Marathon-Ready TM cDNA Human Tests (Clontech).
- PS A loop structure region called a lip that is characteristic of PLA or lipase, and is characterized by an active triad amino acid residue or a steric structure near an active pocket.
- SEQ ID NO: 7 (Primer C: 5'-CGCGGAT CC AT GTTGC TCAAA TG TT TACA TAAT- 3,) or SEQ ID NO: 8 in the sequence listing (P rimer D: 5 1 -CG CGGA TCCA TG AG AG TA TACA TTTT TC TT TG T- 3,) and SEQ ID NO Riva one Supuraima first and to sequence listing 9 (Primer E: 5'-AAAT AT GCG G CCGC T TA TGTGT TC TT TG GTG TACA TGT—3 ') Combined with the oligonucleotide of nucleotide sequence of human testis R ⁇ A (C 1 ontech) using RT-PCR.
- the amplified two gene fragments (approximately 1.7 kbp) were ligated to BamHI / NotI restriction enzyme sites in the multiple cloning site of plasmid pFASTBac1 (Lifetech Oriental). After integration into E. coli JM109, a positive clone was selected and cloned. The plasmid was recovered, and the nucleotide sequence was confirmed by a conventional method.
- a plasmid (pFASTBac-PAPLAlp) having a code region (corresponding to short-type) of the nucleotide sequence of SEQ ID NO: 3 in the sequence listing is provided under the accession number FERMP-1 18072 as an independent administrative institute of AIST.
- Biological Depositary Center (former name: Institute of Biotechnology and Industrial Technology, National Institute of Advanced Industrial Science and Technology) (Address: 1-1-1, Tsukuba-Higashi 1-chome, Ibaraki, Japan 305-8566, Japan) 2000 Deposited on October 5th. Further, the plasmid was transferred to an international deposit in accordance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms in Patent Procedures on August 8, 2001, with accession number FE RM BP-769 7 Is given.
- the cDNA described in SEQ ID NO: 3 (short-type) or SEQ ID NO: 4 (long-type) in the Sequence Listing is composed of 460 or 481 amino acid residues respectively in SEQ ID NO: 1 or 2 in the Sequence Listing. It contains an open reading frame consisting of 1380 or 1443 bases each, which can encode a protein, and has at least the region predicted to be a signal sequence at the N-terminal region in SEQ ID NO: 3 (short-type). Was.
- Amino acid sequence features include N- ⁇ P ⁇ -[ST]- ⁇ P ⁇ ., A motif of asparagine glycosylation site, in two places for both short and long-type (N (A sn ) 63— L (L eu) 66 and N (A sn) 396-S (S er) 399 and N (A sn) 84 — L (L eu) 87 and N (A sn) 4 17-S (Ser) 420)).
- vitellogenin which is considered to have a region that is highly homologous to lipase in steric structure, was also high.
- vitellogenin in short and long-type polypeptides of the present invention, , S (Ser) 159, D (A sp) 183, H (His) 253 and S (Ser) 180, D (A sp) 204, H (His) 274) Since these sequences were confirmed, the sequences were analyzed for multiple alignment using the GENETYXMu1 tip1eA1ig nment module (Software Development Co., Ltd.).
- a loop structure (P (Pro) 239—K (Lys) 250), which exists in the vicinity of the pocket where the active triad is present in a three-dimensional structure and regulates the expression of lipase activity, is present.
- P (Pro) 260 -K (Lys) 271) were found to have the same number of residues as that of PS—PLA, that is, 12 residues.
- lipases other than PS-PLA usually have a long number of amino acid residues in the lip structure, and their activity is expressed by binding of a proteinaceous factor called colipase (BBA , 1 376, 41 7—432, 1998) (Biochemistry, 32, 4702—47 07, 1993) (protein nucleic acid enzyme, 44, 1038-1042, 1999)
- colipase proteinaceous factor
- a PCR fragment of about 0.5 kbp which is a cDNA fragment in the open reading frame, was used as a probe. That is, as a PCR primer, AAAAACACCAGAAAAGTTGCTGTGAG (forward primer—sequence: corresponding to base numbers 493 to 518 of the base sequence of SEQ ID NO: 3) described in SEQ ID NO: 10 in the sequence listing and SEQ ID NO: 11 in the sequence listing GCTTGATAACCCAGCCGAGGACATG (reverse primer sequence: An oligonucleotide represented by the nucleotide sequence of SEQ ID NO: 3 (corresponding to the complementary strand of nucleotide numbers 1001 to 1025) was synthesized and subjected to PCR to prepare a 32 P-labeled probe.
- Northern blotting was carried out using a Human Multiple T issue N othern B 1 ot (CI ontech) according to a user manual (PT1200- ⁇ C 1 ⁇ tech).
- CI ontech Human Multiple T issue N othern B 1 ot
- a user manual PT1200- ⁇ C 1 ⁇ tech.
- the novel PLA of the present invention has the highest amino acid sequence homology (about 45%) with PLA (Japanese Patent Application No. 11-87089), which hydrolyzes on PA to produce 2-acyl LPA. ), It was considered possible to have the activity of Haru. Therefore, it is possible that the new PLA, as a function in vivo, produces LPA and supplies it to the LPA receptor as a ligand.
- EDG2, EDG4, and EDG7 are known LPA receptors. Among them, EDG7 has a strong reactivity with LPA containing unsaturated fatty acids, and is more reactive than 1-acy-LPA.
- the novel PL was expressed in Sf9 cells using the Bacchus virus system described above (hereinafter sometimes referred to as the enzyme side). That is, the recombinant pFAST Bac plasmid cloned above was transfected into a DH10 BAC TM combi tent cell (GI BCO BRL), and the recombinant B acmid was recovered. The resulting B Acmid were WINCH Ransufue Kushiyon in Sf 9 cells with Ce l 1 F ECT IN TM (from cabbage armyworm S podopterafrugi pe rda pupal ovarian tissue). As a result, a recombinant baculovirus (Bacu1oVirus) was recovered in the culture supernatant.
- Bacchus virus system described above (hereinafter sometimes referred to as the enzyme side). That is, the recombinant pFAST Bac plasmid cloned above was transfected into a DH10 BAC TM combi tent cell
- the change in the Ca 2+ concentration was measured using the Ca 2+ fluorescent indicator F ura-2.
- the S f 9 cells expressing LPA receptors S f 9 force Rushiumuatsusi for nutrient solution (1 0 mM C a C 1 2J 60 mM KC 1, 1 7 mM M g C 1 2, 1 0 mM N a C 1, 10 m M ME S, 4 m M X glucose, 11 OmM sucrose, 0.1% ⁇ serum albumin) were suspended to give 5 x 10 5 cells Zm 1, and 2 MF ur 32-—1 ⁇ 1 was incubated at 27 ° 0. Allowed for 1 hour.
- the cells were suspended in the above nutrient solution at a concentration of 5 ⁇ 10 5 cells / ml.
- S f 9 cells newly PLA, has been expressed is suspended so that 5 X 1 0 5 cells / 50 ⁇ 1 in the nutrient solution and incubated for 30 minutes.
- CAF-110 type intracellular ion measurement device JASCO Corporation. To this, 50 ⁇ l of the novel PLA-expressing cells were added, and the same measurement was performed.
- [C a 2+ ] (n M) 224 xb / ax (F-F min) / (Fmax
- 224 is the dissociation constant of F ura 2
- a is the total by adding Triton X-100 F ura 2 and the fluorescence intensity by 38 0 nm excitation light when the extracellular C a 2 + bound
- b is when the F ura 2 total C a 2 + is sharp one Bok added EG TA is dissociated
- 380 F is the ratio of fluorescence intensity due to 340 nm excitation light
- F is the ratio of fluorescence intensity due to 380 nm excitation light
- F max is the total F ura 2 and extracellular C a 2 with Triton X—100 F and F min when + is bound are F when F ura 2 is dissociated by addition of EGTA and all C a 2 + are removed.
- Phospholipase D which converts membrane phospholipids to PA
- PLD Phospholipase D
- the above-mentioned novel PLA1-expressing Sf9 cells were treated with actinomycete-derived PLD, and the culture supernatant 30 minutes later was collected.
- the culture supernatant was allowed to act on Sf9 cells expressing PA receptor EDG7, and intracellular calcium was measured as described above.
- an intracellular Ca response was induced at a lower concentration than when PLD was not treated.
- LPA probably 2-acyl-1-1 yso PA
- the present invention provides PLA, a new PLA belonging to the lipase family.
- Novel PLA is a cell-binding glycoprotein with substrate specificity for phosphatidic acid (PA), which hydrolyzes PA to produce lysophosphatidic acid (LPA).
- PA phosphatidic acid
- the present invention provides a novel PA-specific lipase (LPA production in cells by PL and the mechanism of delivery of LPA from cells to the LPA receptor EDG7).
- Discovery provides a clue to elucidate the physiological significance of the PLA family and the mechanism of producing LPA receptor ligands, and to provide new pharmaceutical compositions and medical treatment tools using this knowledge Offers significant utility in rivase-related clinical and basic medical areas
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01956958A EP1329501A4 (en) | 2000-10-11 | 2001-08-20 | NEW PLA1 |
US10/398,869 US20040253221A1 (en) | 2000-10-11 | 2001-08-20 | Novel pla1 |
CA002425845A CA2425845A1 (en) | 2000-10-11 | 2001-08-20 | Novel pla1 |
JP2002534500A JPWO2002031131A1 (ja) | 2000-10-11 | 2001-08-20 | 新規pla1 |
AU2001278773A AU2001278773A1 (en) | 2000-10-11 | 2001-08-20 | Novel pla1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-311015 | 2000-10-11 | ||
JP2000311015 | 2000-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002031131A1 true WO2002031131A1 (fr) | 2002-04-18 |
Family
ID=18790861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/007106 WO2002031131A1 (fr) | 2000-10-11 | 2001-08-20 | Nouvelle phospholipase a1 (pla1) |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040253221A1 (ja) |
EP (1) | EP1329501A4 (ja) |
JP (1) | JPWO2002031131A1 (ja) |
AU (1) | AU2001278773A1 (ja) |
CA (1) | CA2425845A1 (ja) |
WO (1) | WO2002031131A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003055995A2 (en) * | 2001-12-21 | 2003-07-10 | Xiao-Yan Wen | Lipase genes and proteins |
WO2003072767A2 (en) * | 2002-02-27 | 2003-09-04 | Bayer Healthcare Ag | Regulation of human lipase |
JP2008502312A (ja) * | 2003-11-26 | 2008-01-31 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | ヒトIgGFcレセプターIIb(FcγRIIb)に結合する物質 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107354207B (zh) * | 2017-07-11 | 2019-12-10 | 大连晶泰生物技术有限公司 | 基于双链探针的液相杂交捕获试剂盒、洗涤试剂盒及其应用 |
CN111518814B (zh) * | 2020-05-19 | 2022-07-01 | 西南大学 | 甘蓝型油菜Bna.A05DAD1基因的应用及方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10201479A (ja) * | 1997-01-23 | 1998-08-04 | Toray Ind Inc | フォスフォリパーゼa1 及びそれをコードする核酸 |
WO1999057132A1 (en) * | 1998-05-07 | 1999-11-11 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO2000024911A2 (en) * | 1998-10-27 | 2000-05-04 | Incyte Pharmaceuticals, Inc. | Human phospholipases |
WO2001032885A2 (en) * | 1999-11-05 | 2001-05-10 | Millennium Pharmaceuticals, Inc. | Human lipase |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001243142A1 (en) * | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2002024898A2 (en) * | 2000-09-25 | 2002-03-28 | Millennium Pharmaceuticals, Inc. | 47647, a human lipase and uses therefor |
WO2002063005A2 (en) * | 2001-02-06 | 2002-08-15 | Incyte Genomics, Inc. | Lipid-associated molecules |
US20030044813A1 (en) * | 2001-03-30 | 2003-03-06 | Old Lloyd J. | Cancer-testis antigens |
-
2001
- 2001-08-20 CA CA002425845A patent/CA2425845A1/en not_active Abandoned
- 2001-08-20 AU AU2001278773A patent/AU2001278773A1/en not_active Abandoned
- 2001-08-20 EP EP01956958A patent/EP1329501A4/en not_active Withdrawn
- 2001-08-20 US US10/398,869 patent/US20040253221A1/en not_active Abandoned
- 2001-08-20 JP JP2002534500A patent/JPWO2002031131A1/ja active Pending
- 2001-08-20 WO PCT/JP2001/007106 patent/WO2002031131A1/ja not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10201479A (ja) * | 1997-01-23 | 1998-08-04 | Toray Ind Inc | フォスフォリパーゼa1 及びそれをコードする核酸 |
WO1999057132A1 (en) * | 1998-05-07 | 1999-11-11 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO2000024911A2 (en) * | 1998-10-27 | 2000-05-04 | Incyte Pharmaceuticals, Inc. | Human phospholipases |
WO2001032885A2 (en) * | 1999-11-05 | 2001-05-10 | Millennium Pharmaceuticals, Inc. | Human lipase |
Non-Patent Citations (3)
Title |
---|
HIGGS H.N. ET AL.: "Cloning of a phosphatidic acid-preferring phospholipase A1 from bovine testis", J. BIOL. CHEM., vol. 273, no. 10, 1998, pages 5468 - 5477, XP002949599 * |
SATO T. ET AL.: "Serine phospholipid-specific phospholipase A that is secreted from activated platelets. A new member of the lipase family", J. BIOL. CHEM., vol. 272, no. 4, 1997, pages 2192 - 2198, XP002949598 * |
See also references of EP1329501A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003055995A2 (en) * | 2001-12-21 | 2003-07-10 | Xiao-Yan Wen | Lipase genes and proteins |
WO2003055995A3 (en) * | 2001-12-21 | 2003-11-20 | Xiao-Yan Wen | Lipase genes and proteins |
WO2003072767A2 (en) * | 2002-02-27 | 2003-09-04 | Bayer Healthcare Ag | Regulation of human lipase |
WO2003072767A3 (en) * | 2002-02-27 | 2004-03-11 | Bayer Healthcare Ag | Regulation of human lipase |
JP2008502312A (ja) * | 2003-11-26 | 2008-01-31 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | ヒトIgGFcレセプターIIb(FcγRIIb)に結合する物質 |
US8853363B2 (en) | 2003-11-26 | 2014-10-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Substance binding human IgG Fc receptor IIb (FcγRIIb) |
Also Published As
Publication number | Publication date |
---|---|
US20040253221A1 (en) | 2004-12-16 |
EP1329501A4 (en) | 2004-09-01 |
CA2425845A1 (en) | 2003-04-11 |
EP1329501A1 (en) | 2003-07-23 |
AU2001278773A1 (en) | 2002-04-22 |
JPWO2002031131A1 (ja) | 2004-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Contos et al. | Lysophosphatidic acid receptors | |
WO2014007369A1 (ja) | Fgfr2融合遺伝子 | |
Hasler et al. | cDNA cloning, structural features, and eucaryotic expression of human TAG‐1/axonin‐1 | |
WO2002002762A1 (fr) | Nouvelle lipase | |
EP1019502A2 (en) | Human orphan receptor ntr-1 | |
Seron et al. | A GPI-linked carbonic anhydrase expressed in the larval mosquito midgut | |
WO2002031131A1 (fr) | Nouvelle phospholipase a1 (pla1) | |
JP2005505237A (ja) | スルファターゼおよびそれらの使用の方法 | |
JP2003534765A (ja) | 単離されたvshk−1レセプターポリペプチドおよびそれを使用する方法 | |
JP2003523740A (ja) | 脂質代謝酵素 | |
JP2002508934A (ja) | Tnfレセプターに対して相同性を有する、新規な核酸およびポリペプチド | |
US6444430B1 (en) | Ndr2-related proteins | |
Grahnert et al. | The orthologue of the" acatalytic" mammalian ART4 in chicken is an arginine-specific mono-ADP-ribosyltransferase | |
CN100467601C (zh) | 作为ⅱ型糖尿病靶标的pim-3激酶 | |
US20030113846A1 (en) | Lipid metabolism enzymes | |
JP2007532127A (ja) | 新規のAChE変異体 | |
US20030152963A1 (en) | Human chromosome 15 and 16 bardet-biedl syndrome polynucleotides and polypeptides and methods of use | |
EP1180243B1 (en) | Uses of notch related genes | |
TW202313972A (zh) | 新nrg1融合物、融合接合處及檢測彼等之方法 | |
US20020127636A1 (en) | Ankyrin repeat domain 2 protein variant | |
Crawford | A Novel Laminin Reœptor Expresscd by Invasive Mesenchyme CeUs Drriag GastruIrti011 in! ha Urchin Embryos | |
JP2004261001A (ja) | 新規リパーゼ | |
WO2004066926A2 (en) | Methods and compositions for modulating t lymphocytes | |
JP2003235578A (ja) | 酸性アミノ酸を輸送するナトリウム非依存性トランスポーター及びその遺伝子 | |
JP2002238578A (ja) | ラットedg7受容体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002534500 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2425845 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001956958 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001956958 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10398869 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001956958 Country of ref document: EP |